Verrica Reports $5 Million Q1 Revenue as Wycanth Grows and Phase 3 Wart Program Advances

Overview

• Verrica said Q1 revenue totaled $5 million, with U.S. Wycanth sales up 25.4% compared with the same quarter last year.
• The company posted a net loss of $9.7 million and said its cash can fund operations into the first quarter of 2027.
• The Phase 3 program for common warts passed 50% enrollment in its first trial, and the company plans to start a second trial by mid‑2026.
• Verrica is widening access to YCANTH through a Japan launch, plans for a European Union submission, and a new WycanthRx service that routes prescriptions to partner pharmacies.
• CEO Jayson Rieger will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, with a live webcast available to investors.